Do Nanoparticles Called Dendrimers Offer Promise For Treating Macular Degeneration and Retinitis Pigmentosa?
December 20, 2011
Researchers at the Mayo Clinic, The Wilmer Eye Institute of Johns Hopkins, and Wayne State University’s Kresge Eye Institute recently announced a new approach to treating retinal disease by which steroids attached to nanoparticles called dendrimers were successfully delivered to the retina in a manner that targeted only those cells causing damage, while leaving the rest of eye unaffected.
Researchers believe that their targeted, sustained release drug approach can be used to treat both age-related macular degeneration and retinitis pigmentosa. Both conditions are caused by neuroinflammation, which was relieved by the drug delivery system the researchers developed.
To learn more, click here to read the announcement issued by the Mayo Clinic, which includes a video by one of the researchers explaining the technique.
Click here to read an abstract of the research published in the Biomaterials journal
Comments
Jump down to form below to submit your own comments
